Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharp and Dohme’s pembrolizumab accepted for UK EAMS programme

Merck Sharp and Dohme’s pembrolizumab accepted for UK EAMS programme

11th March 2015

Merck Sharp and Dohme has announced that its anti-PD-1 therapy pembrolizumab has become the first treatment to be accepted under the UK's new Early Access to Medicines Scheme (EAMS).

The drug, which is approved in the US and has received the Promising Innovative Medicine designation in the UK, has been accepted under the scheme for the treatment of advanced melanoma, based on the significance of its early study findings and unmet medical need.

Introduced last year by the Medicines and Healthcare Products Regulatory Agency, the EAMS aims to help NHS patients benefit from promising, innovative treatments before a European licence has been granted.

To date, more than 3,500 patients in over 40 countries have received early access to pembrolizumab – marketed in the US as Keytruda – for the treatment of advanced melanoma through the company's global expanded access programme.

Mike Nally, managing director for Merck Sharp and Dohme in the UK and Ireland, said: "We welcome the government's proactive approach in facilitating early access to medicines for critically ill patients and are delighted that pembrolizumab will be the first innovative medicine to be available to patients through the Early Access to Medicines Scheme."

Earlier this month, the company allied with Eisai on a project that aims to evaluate pembrolizumab in combination with Eisai's oncology compounds Lenvima and Halaven in multiple clinical studies.ADNFCR-8000103-ID-801779166-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.